Notice of Annual General Meeting 2025
Telix announces its Annual General Meeting of shareholders to be held at
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
Telix today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan) in recurrent high-grade glioma (brain cancer), substantiating the patient benefit seen in the IPAX-1 study.
Illuccix® Prostate Cancer PSMA-PET Imaging Agent Approved in Sweden
Telix today announces that its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by the Swedish MPA for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, a broad clinical label. This approval enables healthcare providers in Sweden to offer PSMA-PET imaging using a clinically validated gallium-based radiopharmaceutical.
Telix Announces Cardinal Health for Gozellix Commercial Distribution
Telix today announces that it has selected Cardinal Health, Inc. (NYSE: CAH, Cardinal Health) as one of its commercial radiopharmaceutical distributors to supply finished unit doses of Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix’s next-generation PSMA-PET imaging[1] agent for prostate cancer in the United States (U.S.).
Telix Responds to Recent U.S. Government Actions
Telix advises that it does not expect any material impact on its business or supply chain as the result of the international trade tariffs levied by the U.S. government, announced on 2 April 2025.
Telix Appoints Paul Schaffer as Chief Technology Officer
Telix today announces that is has appointed Dr. Paul Schaffer to the newly created role of Chief Technology Officer (CTO), effective today.
Anne Whitaker Appointed as Non-Executive Director
Telix today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April 2025
Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma
Telix today announces that a first patient has been dosed in the Phase 1 ZOLAR[1] trial of TLX300-CDx (89Zr-olaratumab) in patients with advanced, metastatic soft tissue sarcoma (STS) at the Melbourne Theranostic Innovation Centre (MTIC) in Melbourne, Australia.
FDA Approves New Prostate Cancer Imaging Agent Gozellix®
Telixtoday announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Gozellix® (TLX007-CDx, kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix’s next-generation PSMA-PET imaging[1] agent for prostate cancer.
Telix at EAU25
Join Telix this week at Europe’s largest urological event, the 40th Annual European Association of Urology Congress (EAU25) being held in Madrid, Spain.
Telix’s Phase 3 ProstACT Global study of lead PSMA-targeting radio antibody-drug conjugate candidate TLX591 will be presented alongside a series of presentations on SENSEI®, Telix’s miniature robotic-assisted gamma probe for radio-guided surgery.